GEA Group’s Post

Innovation is not just about technology. The more I progress in my career, the more I realize that innovation creates real impact when it connects science, industry, and real-world needs. Looking back, my journey has taken me through food manufacturing, industrial R&D, ingredient consulting, startup evaluation, and food biotechnology research. Each experience has reinforced one belief: Scientific knowledge creates its greatest value when it becomes a solution that people and industries can actually use. This is the direction that inspires me the most, and where I hope to continue growing and contributing. What does innovation mean to you? 🚀 #FoodTech #FoodInnovation #Biotechnology #Innovation #TechnologyTransfer #AgriFood #ResearchToImpact #SustainableSolutions #ScienceToImpact

“At scale, the real bottlenecks are the ones that quietly add risk, eat into profitability and undermine process efficiency.” Scientific innovation may be the starting point for food biotechnology, but successful scale-up depends on what happens beyond the laboratory. Speaking to New Food Deputy Editor Ben Cornwell, Ola Elmqvist, President of Food Manufacturing Technologies Europe (FMTE), discusses the engineering realities that can determine whether a promising process becomes commercially viable. Read the full article here: https://lnkd.in/eh_Af7qn

MRPI Biotech can collaborate with research institutions, universities, government agencies, agribusiness companies, investors, and national or international organizations in the development, production, and distribution of plant tissue culture technologies.

Acid Alert has recently received support from VLAIO through a spin-off Innovation Mandate and KU Leuven's Industrial Research Fund (IOF). Acid Alert is a sensor technology for monitoring volatile acids in food processing environments. These projects support complementary aspects of the Acid Alert roadmap and will help advance the technology towards pilot-line demonstration in potato blanching processes. See the comments for more information on Acid Alert, or get in touch.

It amazes me how much of a drug approval hinges on *not* its efficacy. >50% of Complete Response Letters are form manufacturing controls. And it's regardless of the modality. Learn from discussions like these: don't get trapped in FDA purgatory. Start with the end in mind!

Manufacturing and CMC account for 64% of drug launch delays—not the science or discovery. The key challenge in innovation lies in scaling it effectively. As we wrap up #BIO2026, the conversation emphasizes this crucial point. We're at booth 2027 for another day, ready to discuss further. A huge thank you to STAT Brand Studio, Jesse McQuarters, Rick Berke, and our esteemed speakers, including Aimee Wang, Fareborz Zock Zamaniyan, and Pierre-Alain Ruffieux.

What if the biggest innovation isn’t a product? When we think about innovation, we often picture the final result. A new ingredient. A new technology. A new product. But behind every breakthrough lies something less visible. Years of research. Countless iterations. Quality systems. Regulatory pathways. Collaboration across disciplines. The product is what reaches the market. The process is what makes it possible. As biotechnology continues to evolve, the companies creating lasting impact will be those that invest not only in innovation itself, but also in the systems that allow innovation to scale responsibly. Because sustainable progress is rarely built on one great idea. It is built on thousands of well-executed decisions. #Tecmafoods #Biotechnology #Innovation #FoodInnovation #FutureOfFeed #Quality Image generated by AI.

One of the biggest questions for companies building cell free and enzyme driven manufacturing platforms is not whether the biology works- It's whether the enzymes can be produced economically at commercial scale.   At Alagene Ltd., we're seeing growing demand from companies that want to answer these questions early. The right expression host, achievable yields, low-cost downstream strategy, and techno economic targets all need to be considered before committing significant resources.   That's exactly why we developed our enzyme production feasibility sprint, helping companies identify the most practical and cost effective path to manufacturing before scale up becomes the bottleneck.   We are excited to see more innovation in this space and looking forward to supporting the next generation of enzyme enabled manufacturing platforms. Yoav Keshet Hadar Fairstein Meital Pinchas Noam Deouell Oz Reuveni Roni Cohen Zusman Vivian Shemesh Neta Agmon Kevin Gray Dan Siegal Israel Innovation Authority רשות החדשנות hylabs (Hy Laboratories Ltd) Dotan Borenstein Shai Melcer Ronit Eshel Aviv Zeevi Balasiano

Nature continues to be one of the greatest sources of innovation, but unlocking its full potential requires new ways of discovering and validating bioactive ingredients. That’s why we’re excited to announce a strategic partnership between Nanyang Biologics (NYB) and Sweetch Group. By combining expertise in natural compound discovery, artificial intelligence, and green chemistry, this collaboration will accelerate the identification of high-potential bioactive molecules while enhancing the speed, precision, and scientific confidence behind ingredient development. Together, we’re helping shape the future of cosmetic ingredient innovation, where nature and technology work hand in hand to deliver high-performance, sustainable solutions. 🔗 Read the full announcement: https://lnkd.in/eRWXntVR

One of the biggest questions for companies building cell free and enzyme driven manufacturing platforms is not whether the biology works - It's whether the enzymes can be produced economically at commercial scale. At Alagene Ltd., we're seeing growing demand from companies that want to answer these questions early. The right expression host, achievable yields, low-cost downstream strategy, and techno economic targets all need to be considered before committing significant resources. That's exactly why we developed our enzyme production feasibility sprint, helping companies identify the most practical and cost effective path to manufacturing before scale up becomes the bottleneck. We are excited to see more innovation in this space and looking forward to supporting the next generation of enzyme enabled manufacturing platforms. Yoav KeshetOrly Savion , PhDNeta AgmonRoni Cohen ZusmanVivian ShemeshHadar FairsteinNoam DeouellOz ReuveniMeital PinchasKevin GrayDan Siegalhylabs (Hy Laboratories Ltd)Ronit EshelShai Melcer